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Abstract.  A  specific surface receptor for urokinase 
plasminogen activator (uPA) recognizes the amino- 
terminal growth factor-like sequence of uPA, a  region 
independent from and not required for the catalytic ac- 
tivity of this enzyme. The properties of the uPA recep- 
tor (uPAR) and the localization and distribution of 
uPA in tumor cells and tissues suggest that the 
uPA/uPAR interaction may be important in regulating 
extracellular proteolysis-dependent processes (e.g.,  in- 
vasion, tissue destruction). Phorbol myristate acetate 
(PMA),  an inducer of U937 cell differentiation to mac- 
rophage-like cells, elicits a  time- and concentration- 
dependent increase in the number of uPAR molecules 
as shown by binding, cross-linking, and immunopre- 
cipitation studies. The effect of PMA is blocked by 
cycloheximide. Overall,  the data indicate that PMA in- 
creases the synthesis of uPA. 
PMA treatment also causes a  decrease in the affinity 
of the uPAR for uPA, thus uncovering another way of 
regulating the interaction between uPA and uPAR. In 
addition, the PMA treatment causes a modification of 
migration of the cross-linked receptor in mono- and 
bidimensional gel electrophoresis. 
T 
wo  enzymes  activate  plasminogen  into  the  broad- 
spectrum  protease  plasmin:  urokinase  (uPA)  ~ and 
tissue-type plasminogen activator (12). Available evi- 
dence indicates that the activation of plasminogen to plas- 
min, in addition to regulating intravascular fibrinolysis, also 
regulates extracellular proteolysis in tissues.  Extracellular 
proteolysis is involved in cellular migration, tissue destruc- 
tion, and invasiveness (20, 50). In such processes, the attach- 
ment and detachment of cells to and from neighbor cells or 
extracellular matrix must occur via the  sequential break- 
down and  reformation of protein  bonds  that provide  an- 
chorage sites.  Urokinase activity has been shown to be re- 
quired in the degradation of the extracellular matrix, in the 
invasion of basement membrane by tumor cells, and in many 
of the transformation parameters of Rous  sarcoma virus- 
transformed chicken embryo fibroblasts in vitro (8, 37, 60). 
In vivo,  inhibitory anti-uPA  antibodies block metastasis in 
two experimental systems: the human HEp3 carcinoma in 
the chorion allantoid membrane of the chicken embryo (45) 
and the mouse B16 F10 melanoma injected intravenously into 
syngeneic animals (29).  Immunocytochemical studies have 
localized uPA within the invasive part of the Lewis lung car- 
1. Abbreviations  used in this paper: ATE amino-terminal fragment; DSS, 
disuccinimidyl-suberate; PMA, phorbyl-12-myristate-13-acetate; uPA, uro- 
kinase plasminogen activator; uPAR, urokinase plasminogen activator re- 
ceptor. 
cinoma in cells that are in proximity to the remnants of the 
invaded normal tissues (56).  In human cells, uPA has been 
located on the outer surface of several cells (3, 58) and at dis- 
crete cell-cell and cell-substratum contact sites (30, 47, 48). 
Several normal and malignant cells in culture (4,  13, 26, 
32, 57, 58, 63), as well as human tumor specimens (39), have 
been shown to possess a specific surface receptor for uPA 
that on some cell types has been identified as a glycoprotein 
with an Mr of 55,000-60,000 (41). The amino acid sequence 
of uPA  responsible  for binding to  the  receptor  has  been 
located within the amino-terminal fragment (ATF) of the 
molecule (58) within residues 12-32 (2).  The uPA receptor 
(uPAR) (10) binds both uPA and pro-uPA and can serve as 
an activation site for conversion of the single-chain pro-uPA 
to active two-chain uPA by plasmin (19). This is in keeping 
with previous observations (57, 63) that showed little, if any, 
internalization or down-regulation of the uPAR.  Actually, 
receptor-bound uPA dissociates very slowly with a half-life 
of'~ 3 h (Cubellis, M. V., and E Blasi, unpublished observa- 
tions) and remains active at the surface of the cells (63). 
These properties suggest that the uPAR may serve to focal- 
ize uPA activity on the cell surface by mediating the activa- 
tion of pro-uPA and the action of uPA. This, in turn, should 
allow the cell surface to regulate both intravascular fibrinoly- 
sis and the extravascular extracellular matrix and basement 
membrane degradation (14). The production of uPA by ma- 
lignant cells and its binding to the uPAR of the same cells 
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of the malignant (invasive) phenotype, facilitating the spread- 
ing and the invasion of tumors (14). 
While a  surface proteolytic activity may have important 
and specific physiological and developmental functions, its 
activity needs to be carefully controlled; improper regula- 
tion might cause a loss of the coordination of different reac- 
tions required for cell migration or could provide the cells 
with the capacity to destroy and/or invade the surrounding 
tissues. 
The expression of the uPA gene is finely regulated by a va- 
riety of agents that affect cell growth (7,  11, 20, 21, 38, 59); 
however, very little is known of the regulation of the uPAR 
function and synthesis. We have previously observed a spe- 
cific increase of uPA binding to human U937 cells after dif- 
ferentiation to macrophage-like cells induced by treatment 
with phorbol-12-myristate-13-acetate  (PMA)  (41). We now 
report a detailed analysis of the effect of PMA on uPARs in 
U937 cells. Our data show that in these cells PMA exerts a 
complex regulation of the interaction of uPA with uPARs by 
stimulating the  synthesis of uPARs  and by decreasing its 
affinity for uPA. 
Materials and Methods 
Materials 
Human  urinary  urokinase of high (uPA)  and low (33K uPA)  Mr and its 
amino terminal fragment (ATF) were prepared as described (57). PMA (LC 
Service, Woburn, MA) was dissolved at 1 mg/ml in DMSO and diluted to 
working  concentration with  RPMI  1640  medium  (Gibco  Laboratories, 
Grand Island, NY) supplemented with 10%  beat-inactivated FBS (Gibco 
Laboratories).  Ampholines were purchased from  LKB Instruments Inc. 
(Bromma, Sweden). 
Cell Culture 
U937  cells (57)  were grown in RPMI  1640  medium supplemented with 
heat-inactivated FCS. 
Radio-iodination and Receptor-binding  Assay 
ATF and uPA iodination with Nal2SI and binding of iodinated ATF and 
uPA to U937 cells have been described (57).  For each binding assay,  5  × 
106 cells were resuspended in  1.0 ml of binding buffer (PBS containing 
0.1% BSA), and challenged for 1 h at 23°C with 1.5  ×  105 cpm (i.e., ~70 
fmol) iodinated ligand. Binding saturation curves were obtained by includ- 
ing varying amounts of unlabeled ligand in the binding mixture. Specificity 
was tested by competition with excess unlabeled ATE uPA, pro-uPA and 
low-Mr uPA. When required, cells were acid washed before the binding as- 
say for 3 rain in 50 mM glycine-HCl, pH 3.0, 0.1 M NaCI, quickly neutral- 
ized, and washed (58). 
Phorbol Ester-induced Differentiation 
U937 cells were resuspended at 0.2-0.5  x  106/ml and incubated with 150 
nM PMA in RPMI  1640  medium (Gibco Laboratories) containing 10% 
heat-inactivated FBS. Differentiation was routinely followed by estimating 
the percentage of cells acquiring the property of adhering to the plastic dish 
and occasionally by the ability to incorporate latex beads by phagocytosis 
(17). Binding of 125I-ATF or uPA to differentiated cells was carried out as 
described (57). 
Cross-linking of  uPAR to Intact Cells 
U937 cells (40 ml at 0.5  x  106/ml) were induced with 150 nM PMA for 
60 h. At this time, nonadherent cells were removed by aspiration; the adher- 
ent cells were gently washed and then resuspended by vigorous pipetting. 
Induced or noninduced cells were first incubated in serum-free RPMI-1640 
medium  for 2  h  at  37°C.  One  million control  or  PMA-induced cells, 
resuspended in 0.2 ml of binding buffer,  were incubated in duplicate with 
IzSI-ATF (50,000  cpm, 25 fmol) for 2 h at 4°C with or without unlabeled 
ATE The binding step was terminated by washing the cells twice with bind- 
ing buffer.  For cross-linking, 0.2 vol of disuccinimidyl-suberate (DSS) (1.0 
mM in DMSO) was added and the cells were incubated 15 min at room tem- 
perature. Cross-linking was stopped by the addition of 10 mM ammonium 
acetate (final concentration) followed by incubation for 10 min at room tem- 
perature. The cells were finally washed in binding buffer, centrifuged, and 
the pellet was  resuspended in  50  #1  of 0.7  M  Tris-HCI,  pH 6.8,  10% 
glycerol, 3% SDS, 0.01% bromphenol-blue (35). Each sample was split into 
two, and/3-mercaptoethanol (0.5% final concentration) was added to one 
set. All samples were boiled for 5 min and analyzed by SDS-PAGE (35) on 
a 7.5-15% polyacrylamide gel gradient. Gels were dried and exposed to Ko- 
dak XAR-5 films. 
Immunoprecipitation of the uPA/uPAR Complex 
Control or PMA-treated cells (24 h, 150 nM) were incubated overnight with 
methionine-free medium containing 5% beat-inactivated FCS and [35S]L- 
methionine (100 #Ci/ml). Cells were washed in binding buffer, resuspended 
in the same buffer containing 1.0 nM unlabeled uPA (human urinary uro- 
kinase), and incubated for 1 h at room temperature. After this binding step, 
the cells were washed and cross-linked with DSS, as described above. After 
washing, the cells were lysed in 20 mM Hepes buffer,  pH 7.4,  containing 
1.0% Triton X-100 and 10% glycerol, and the lysate was centrifuged for 30 
min in a microfuge (Eppendorf made by Brinkman Instruments, Inc., West- 
bury, NY) at 4°C. TCA precipitation was carried out on aliquots of the su- 
pernatants. For immunoprecipitation, 2.5  ×  107 cpm of the lysate of the 
cross-linked cells were precipitated with normal  rabbit serum and non- 
specific precipitate was spun down after addition of 50 #l of Staphylococcus 
aureus suspension (51). The supernatants were subsequently immunopre- 
cipitated by incubation with anti-uPA IgG (purified by protein A-Sepharose 
chromatography) overnight at 4°C. S.  aureus suspension (50 ttl) was then 
added, and the samples were incubated for 30 min at 4°C, and centrifuged. 
The pellet was washed five times with 40 mM Hepes, pH 7.4,  1.0 M NaCI, 
0.1%  SDS,  1%  Triton X-100, 0.5%  sodium deoxycholate,  1 mM EDTA, 
0.02 % sodium azide, and then washed five more times with 0.1 M Tris-HC1, 
pH 7.9, 0.5 M LiCI, 0.05%  dithiothreitol (DTT). The final pellets were re- 
suspended in loading buffer with/3-mercaptoethanol (35), boiled for 5 min, 
and centrifuged. The supernatants were analyzed by 12.5 % SDS-PAGE, fol- 
lowed  by  fluorography  along  with  lac-labeled  protein  molecular  mass 
markers. 
Cross-linking Assay of  Solubilized Receptor 
108 PMA-treated or untreated cells were washed, acid treated, and lysed by 
the addition of 2  ml 0.5%  3-[(3-cholamidopropyl) dimethyl-ammonio]-l- 
propanesulfonate in 0.1 M Tris-HCl, pH 8.1, 10 mM EDTA, 1 mM PMSE 
10 #g/ml Trasylol. After 10 rain at 0°C, the lysates were clarified by cen- 
trifugation. 
2 I~1 of supernatant was incubated with 42 nM 1251-labeled ATF in a total 
volume of 6 p.l for 1 h at 4°C.  1 #l of 14 mM DSS in DMSO was added, 
and after 15 rain at room temperature, the reaction was stopped by addition 
of  0.8 #1 of 0.1 M ammonium acetate. The samples were left for 1 h, followed 
by addition of 0.5 % SDS, 0.1 M/3-mercaptoethanol (final concentrations), 
boiled for 3 rain, and then analyzed by SDS-PAGE (6-16%  gradient gel) 
(35)  under reducing conditions and autoradiography. 
Bidimensional Gel Electrophoresis 
Control and PMA-treated U937 cells were cross-linked to 125I-ATF and ex- 
tracted  (see above).  Extracts  were analyzed by  bidimensional gel  elec- 
trophoresis (43),  using a  mixture of 0.8%  ampholines, pH 3.5-10,  0.8% 
ampholines, pH 5-7, and 0.8% ampholines, pH 2.5-5.0. A 7.5% polyacryl- 
amide gel was used in the second dimension. An extract of [35S]methio- 
nine-labeled Escherichia coli was used as internal marker (46). The molec- 
ular  mass (in  amino acid  residues) and  isoelectric point of the marker 
proteins were obtained from the literature (40). 
Results 
Cell Density and PMA Affect uPA Binding to uPARs 
on U937 Cells 
Treatment with PMA induces U937 cells to differentiate to 
macrophage-like cells.  The cells become initially adherent 
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quire complex specialized functions, like phagocytosis (42, 
49). PMA-differentiated U937 cells also show an increased 
binding capacity of uPA to uPARs  (57). 
To gain information on the mechanisms that regulate the 
interaction between uPA and uPARs, we have further studied 
the effect of PMA on U937 cells.  ~25I-ATF, which has all of 
the receptor-binding determinants of uPA (57), was used in 
most of  the experiments instead of labeled uPA. Its use allows 
discrimination from other types of binding sites (including 
inhibitors) that have been shown to require the catalytic moi- 
ety of uPA (1, 5, 24, 31, 64). 
Since one of the effects of PMA is a block of U937 cells' 
proliferation (42), untreated cells ultimately reach a higher 
cell density. We therefore tested whether cell density could 
by itself modify the number of uPAR molecules. The number 
and affinity of uPARs were measured by standard saturation 
binding experiments and Scatchard analysis. As shown in Ta- 
ble I, the titratable number of uPAR molecules drops from 
14,000-18,000 for cells grown at 150,000-300,000 cells/ml 
to 1,800 for cells grown at 1,500,000 cells/ml. As also shown 
in Table I, the affinity of the receptors is not affected. A simi- 
lar effect was observed with U937 cells in which biosynthetic 
uPA or pro-uPA had been dissociated from the receptors (by 
acid treatment) before the binding assay was carried out (see 
Materials and Methods). In this case, the number of ATF- 
specific uPA binding  sites  per cell drops  from 27,000  (at 
180,000 cells/ml) to 9,000 (at 1,500,000 cells/ml). Thus, the 
decrease in number of uPA-binding sites is not, or at least 
not only, due to progressive saturation by biosynthetic ligand 
but rather to a cell density-associated modulation. The na- 
ture of this effect will be the object of future investigation. 
However, to avoid interference between PMA and cell den- 
sity effects, in the experiments described hereafter, untreated 
and PMA-treated cells were plated so that they reached the 
same cell density at the time of the assay. 
We have previously reported an increase in the number of 
uPA binding sites in PMA-treated U937 cells (57), which is 
accompanied by a decrease in ligand affinity (41). We have 
now  analyzed  the  time  and  concentration dependence of 
these effects. Table II shows a quantitation of the effect of 150 
nM PMA at different times of exposure of U937 cells on both 
the uPAR and on the conversion of the cells from the suspen- 
sion-growing to the adherent-growing phenotype. By 24 h, 
essentially all cells are attached and the number ofuPARs has 
Table L  Effect  of Cell Density on the Number and 
Affinity  of uPAR Molecules in  U937 Cells 
uPARs per cell  Kd 
without  with  without  with 
Cell density  acid wash  acid wash*  acid wash  acid wash* 
n  n  nM  nM 
150,000/ml  14,000  ND  0.2  ND 
180,000/ml  ND  27,000  ND  0.5 
300,000/ml  18,000  ND  0.3  ND 
700,000/ml  3,500  ND  0.1  ND 
750,000/ml  ND  12,500  ND  0.3 
1,500,000/ml  1,800  9,000  0.1  0.4 
* U937 cells were treated  before the binding assay with 50 mM glycine-HCl, 
pH 3.0, 0.1  M  NaCI  (see Materials and Methods) to dissociate any surface- 
bound uPA. 
Table II.  Time course of the Effect  of PMA on Number 
and Affinity  of uPAR Molecules on  U937 Cells 
Duration of  Adherent§ 
PMA treatment*  uPARs per cell~  Kd~  cells 
h  n  nM  % 
0  8,200  0,4  2 
24  270,000  4  97 
48  470,000  8  99 
72  810,000  17  99 
* Both control and  150 nM PMA-treated cells had reached a cell density of 
500,000/ml at the time of the assay. 
Data obtained by Seatchard  plot analysis. Specific binding was calculated by 
subtracting the counts not displaced by unlabeled ATF. 
§ Counted after gentle washing of the plates and after resuspension of the ad- 
herent cells by vigorous pipetting. 
increased from 8,000 to 270,000  per ceil while the affinity 
(Kd) is decreased about 10-fold.  A  further twofold increase 
in number and decrease in affinity is observed after 48 h and 
again after 72 h of treatment. In all cases, the binding could 
be competed for by 50 nM unlabeled ATF (data not shown). 
Assays carried out after acid dissociation of biosynthetic uPA 
yielded at each timepoint an approximately twofold higher 
receptor number  with  no  further  change  in  affinity (not 
shown). 
We next measured the effect of PMA concentration on the 
amount of bound t25I-ATF  to cells at 3 or 24 h of treatment. 
As shown in Fig.  1 A, PMA treatment induced an increase 
in ~2~I-ATF binding both at 3 and 24 h, but only at concen- 
trations above 0.15 nM, with a maximum effect between 15 
and 150 nM. These concentrations are within or below the 
range that promotes U937 cell differentiation (49). As shown 
in Fig.  1 B, 0.5 nM unlabeled ATF competes with "~50% of 
the binding in control cells and in cells treated with all PMA 
concentrations for 3 h. At 24 h of PMA treatment, however, 
binding  of ~25I-ATF to cells treated with  1.5  nM  or more 
PMA was no longer competed by 0.5 nM ATE At 50 nM 
ATF, 97 % or more of the counts are competed at all PMA 
concentrations tested (data not shown; see, however, Fig. 2 
B below). 
To test the extent to which the results of Fig. 1 B were due 
to a change in number and affinity, respectively, of the uPARs, 
U937 cells were treated with 1.5 or 15 nM PMA for 3 or 24 h 
and thereafter a saturation binding assay was carried out. As 
shown in Fig. 2, A, and C, the competition curve for the cells 
treated for 24 h with PMA is shifted towards higher concen- 
trations in  relation to control cells.  Scatchard analysis  of 
these data shows (Fig. 2, B and D) that the 24-h treatment 
with 15 nM PMA changes both the slope and the intercept 
with the abscissa of the binding isotherm. From this curve, 
a 40-fold increase in the number of binding sites and a  13- 
fold decrease of the affinity of the uPAR for ATF (Kd shifted 
from 0.3 to 4.0 nM) are calculated (data summarized in Table 
III). A smaller effect is obtained with 1.5 nM PMA for 24 h. 
A very slight effect is observed after 3 h of treatment at both 
PMA concentrations. Assays carried out after acid dissocia- 
tion of biosynthetic uPA yielded qualitatively similar results 
(not shown). 
Increased ATF Binding Is Due To Increased Synthesis 
of uPA Receptor 
The enhanced uPA binding may be due to an actual increase 
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Figure  1.  Concentration dependence of PMA effect on the uPA/ 
uPAR interaction after 3 (o) and 24 h (o) of treatment. (A) % ~25I- 
ATF specifically bound to 106 U937 cells. (B) % bound t2SI-ATF 
that can be displaced by 0.5 nM unlabeled ATE 
in the number of receptor molecules available on the surface. 
To test this possibility, U937 cells (grown at  l@/ml) were 
treated with 150 nM PMA for 60 h, a time that allows expres- 
sion of some differentiated functions, like phagocytosis (data 
not shown). After incubation with the radioactive ATF for 
2 h at 4°C, the ceils were washed and treated with DSS to 
cross-link the  ligand  to the uPAR.  Cross-linked products 
were analyzed by SDS-PAGE after reduction with/~-mercap- 
toethanol. As shown in Fig. 3, ~25I-ATF (lane/) can be cross- 
linked to a cellular component to give a broad band at ~70 
kD  (lanes  6 and  7).  The electrophoretic migration of the 
ATF-uPAR complex (i.e., its corresponding molecular mass 
and the diffusiveness of the band) is a specific property of 
the human uPAR molecule, which is retained with highly 
purified receptor preparations (41; our unpublished results). 
Omission of the reduction of the cross-linked products with 
/3-mercaptoethanol does not influence the migration of the 
complex (not shown). Treatment of U937 cells with PMA in- 
creases severalfold the intensity of the "~70-kD band (lanes 
4 and 5). When binding to both control (lanes 8 and 9) and 
PMA-treated cells (lanes 2 and 3) was carried out in the pres- 
ence of 50 nM unlabeled ATF,  the intensity of the cross- 
linked band is drastically reduced or its presence abolished 
altogether. In conclusion, this experiment identifies an ,'°55- 
kD cellular component that can be cross-linked to ATF and 
shows that its availability on the surface is increased sever- 
alfold after PMA-induced differentiation to macrophages. 
Similar data have also been obtained using labeled uPA as 
ligand (not shown). In addition to ATF, unlabeled uPA and 
pro-uPA, but not the low-Mr uPA (which does not bind the 
uPAR since it is missing the ATF portion [57]), compete for 
cross-linking to U937 cells (data not shown). In the experi- 
ment of Fig.  3, the labeled '2~I-ATF preparation shows  two 
contaminating bands at ,'030,000 and 80,000 D (see lane/). 
Experiments carried out with other labeled ATF prepara- 
tions free from these contaminants give cross-linking results 
identical to those of Fig.  3 (not shown).  These data are in 
complete agreement with those obtained with purified uPAR 
(41). 
The increase in uPARs was also visualized by immunopre- 
cipitation of metabolically labeled uPAR after cross-linking 
with  uPA  using  anti-uPA  antibodies.  Unlabeled  uPA  was 
bound to [3sS]methionine-labeled  U937 cells and then cross- 
linked with DSS. The cells were lysed and aliquots of the la- 
beled cross-linked extract immunoprecipitated with  poly- 
clonal anti-uPA IgG. As shown in Fig. 4, the treatment with 
PMA causes an increase of a diffuse, specifically immuno- 
precipitated band that migrates with an M, of ~70,000. uPA 
(Mr  ~54,000)  is  made  up  of two  disulfide-linked chains 
(28), of which the smaller (A chain, 17 kD) holds the recep- 
tor binding  site (57).  The electrophoretic mobility of the 
immunoprecipitated band after reduction with/3-mercapto- 
ethanol corresponds to the one expected because it is the A 
chain that is  cross-linked to the 55-kD uPAR.  The uPA- 
uPAR complex migrates with a similar Mr as the uPA-PAI-2 
complex of U937 cells (27).  Since PAI-2 is also induced by 
PMA (27) the ~70-kD band of Fig. 4 could also represent 
uPA-PAI-2  complex.  However, the latter complex (a)  has 
never been observed on the cell surface and (b) would not 
be formed at the uPA concentrations used in this experiment 
(15 nM) since the affinity of PAI-2 for uPA is ~2 #M (62). 
Other fainter bands are immunoprecipitated by the anti-uPA 
antibodies (Fig. 4), but their intensity appears to be indepen- 
dent of the PMA treatment.  These may represent biosyn- 
thetic uPA, which is only slightly induced by PMA in U937 
cells  (our unpublished  results),  or complexes of different 
forms of uPA (high- and low-Mr uPA) with plasminogen ac- 
tivator inhibitors that are produced by U937 cells (64). More 
recently, we have used labeled DFP-treated uPA as a ligand 
in the above experiment. While the ~70 kD band is still in- 
creased by PMA, all of the others are no longer present (data 
not shown). 
The  increase  in  uPARs  observed  in  these  experiments 
might result from a PMA-induced translocation of uPARs to 
the surface or from an increase in their synthesis. Two ex- 
periments were carried out to discriminate among these pos- 
sibilities.  In the first, U937 cells (grown at 0.5  ×  106/ml) 
were treated with 150 nM PMA for 24 h in the presence or 
absence of cycloheximide (10 or 50/~g/ml), and the extent 
of '2SI-ATF binding and biological effect of PMA (i.e., the 
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Figure 2.  Effect of PMA treatment on the interaction of ~25I-ATF with uPAR. (o) Control cells; (e) cells treated with 1.5 nM PMA; 
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percentage of adherent cells) was estimated. As shown in the 
histogram of Fig. 5, cycloheximide completely prevents the 
PMA-induced adhesion of U937 cells as well as the increase 
in  ~25I-ATF binding capacity.  This suggests  that increased 
uPA  binding  is  the  result of increased receptor synthesis 
rather than of translocation of cytoplasmic receptors to the 
outer surface. 
To further investigate this  point,  we carried out cross- 
linking experiments with whole cell extracts of control and 
PMA-treated cells. This procedure has been previously de- 
Table III.  Effect  of PMA Treatment  on Number and 
Affinity  of uPAR Molecules in  U937 Cells*: Role of 
Time of Treatment  and PMA Concentration 
uPARs 
Treatment  per cell  Ka 
n  nM 
Control¢  12,500  0.3 
PMA  1.5  nM,  3  h  14,300  0.3 
PMA  15  nM,  3  h  14,900  0.3 
PMA  1.5  nM,  24  h  165,000  1.2 
PMA  15  nM,  24  h  475,000  4.0 
* Data calculated from the experiment of Fig. 2. Specific binding was calculat- 
ed after subtracting the counts not competed by 50 nM ATF unlabeled ATF. 
$ Both treated  and  PMA-treated  U937 cells  had  reached  a  cell density  of 
,',,500,000/ml  at the time of the assay. 
veloped and used to assay for uPAR during its purification 
(41). We cross-linked protein extracts to t25I-ATF and ana- 
lyzed the complex by gel electrophoresis (Fig. 6). In this ex- 
periment, the band obtained with PMA-treated extract (lane 
/) is approximately twofold stronger than that obtained with 
control extract. However, the extract from the PMA-treated 
cells was diluted before cross-linking to contain an eightfold 
lower protein concentration than  the extract from control 
cells. The quantitation and the specificity of the assay was 
controlled by using different extract concentrations and by 
displacement  with  appropriate  uPA  analogs  (not  shown). 
Thus, whole cell extracts of PMA-treated U937 cells contain 
at least 10-fold more uPAR specific activity than do control 
cells. The slightly different electrophoretic mobility of the 
PMA-treated ATF-uPAR complex (compare lanes 1 and 2) 
does not affect this conclusion and is dealt with in the next 
paragraph. 
On the whole, the experiments show that PMA treatment 
of U937 cells results in an increase in number of total uPA 
binding  sites,  that is blocked by cycloheximide treatment, 
and in an increase of metabolically labeled uPARs  as well 
as  of uPARs  detected  by  cross-linking  radioactive  ATE 
We therefore conclude that PMA increases the synthesis of 
uPARs. In further support of  this conclusion, PMA treatment 
of U937 was instrumental in uPAR purification (41; our un- 
published observations). 
Picone et al. Regulation of Urokinase Receptors  697 Figure 3. SDS-PAGE (7.5-15% gradient) of the products of cross- 
linking of ~25I-ATF  with U937 cells. Effect of PMA.  125I-ATF  was 
bound to control and PMA-treated (150 nM, 60 h) U937 cells, and 
cross-linking  was performed  with DSS (see Materials and Meth- 
ods). The samples were denatured and reduced in the presence of 
~-mercaptoethanol.  (Lane 1)  12SI-ATF  preparation  used for bind- 
ing; (lanes 2 and 3) binding to PMA-treated cells in the presence 
of 50 nM unlabeled ATF; (lanes 4 and 5) binding to PMA-treated 
cells;  (lanes 6 and 7) binding to untreated U937 cells; and (lanes 
8 and 9) binding to untreated cells in the presence of 50 nM unla- 
beled ATE The Mr (in kD) of markers subjected to electrophoresis 
in lane M are indicated to the left. 
PMA Treatment Increases the Heterogeneity 
of the uPAR 
PMA treatment of U937 cells, in addition to increasing the 
intensity of the cross-linked uPAR band (Fig. 3), also causes 
a slight retardation of its migration. While this is not particu- 
larly evident in monodimensional gels (Figs.  3 and 6), bi- 
dimensional analysis shows the heterogeneity of the complex 
in a more striking way. Control and PMA-treated (150 nM, 
24 h)  U937 cells were cross-linked to  ~25I ATE lysed, and 
analyzed by bidimensional gel electrophoresis.  The results 
are shown in Fig. 7. The cross-linked uPA-uPAR complex of 
control cells (A) migrates as a double spot of similar molecu- 
lar mass and different isolelectric point (C,  1 and 2).  The 
complex from PMA-treated cells  (B)  separates  into  three 
components, one of which coincides with the control (C, 2) 
while two others (C, 3 and 4) have lower mobility and a more 
acidic isoelectric point. The reasons for uPAR heterogeneity 
are not clear. Posttranslational modifications might account 
for it but have not yet been investigated. 
Discussion 
In this paper,  we have analyzed the effect of PMA on the 
uPARs of U937 cells. 
Figure 4. Immunoprecipitation by anti-uPA IgG of the cross-linked 
uPA/uPAR complex  of U937 cells.  Effect of PMA.  Control  or 
PMA-treated  [3~S]methionine-labeled U937 cells  were  incubated 
with uPA (15 nM), cross-linked with DSS, and lysed. Aliquots of 
the labeled extracts were adsorbed with normal rabbit serum and 
immunoprecipitated with anti-uPA IgG (lanes B and D) or with pre- 
immune IgG (lanes A and C) and subjected to electrophoresis on 
a  12.5% SDS-polyacrylamide  gel (see  Materials  and Methods). 
(Lanes A and B) Untreated cells; (lanes C and D) cells treated with 
150 nM PMA for 24 h. 
(a) We have observed a time- and concentration-dependent 
increase  in  ATF  binding  of U937  cells  upon  addition  of 
PMA. At 150 nM PMA and 24 h of treatment, a 34-fold in- 
crease of uPAR molecules can be measured (Table II). This 
increase has been measured by direct binding (Figs.  1 and 
2), cross-linking (Fig. 3), and immunoprecipitation (Fig. 4). 
(b) Three types of evidence suggest that the increase in 
uPA-binding sites is the result of increased synthesis of uPAR. 
First, an increase in metabolically labeled uPAR is noticed 
after PMA treatment (Fig. 4). Second, the PMA-induced in- 
crease in the number of ATF binding sites is blocked by the 
protein synthesis inhibitor cycloheximide (Fig. 5). Third, the 
uPA-binding protein is increased not only on the membrane 
(Fig.  3) but also in whole cell extracts (Fig.  6). 
(c) After PMA treatment, a decrease in affinity of uPAR 
for ATF is also observed (Table II). This is not due to induc- 
tion by PMA of a binding protein with different specificity, 
as  demonstrated  by  the  competition with  unlabeled  ATF, 
uPA, and pro-uPA, but not with low-Mr uPA. The biochem- 
ical nature of the affinity change has not yet been understood. 
Several models could be envisaged on the basis of present 
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Figure 5.  Effect of protein synthesis inhibitor cycloheximide on the PMA-induced increase in  ~25I-ATF binding (open bars)  and on the 
conversion from suspension-growing to adherent U937 cells (solid bars).  PMA treatment was carried out for 24 h in the presence or absence 
of 10 or 50 #g/ml cycloheximide. 
bTgure 6. Cell-free binding of x25I- 
ATF to total cell extracts of PMA- 
treated (lane/) and control (lane 
2)  U937 cells.  Undiluted (con- 
trol)  or eightfold diluted  (PMA- 
treated)  lysates  of  acid-treated 
cells  were  incubated  with  ~25I- 
ATF, cross-linked with DSS, and 
then analyzed by SDS-PAGE (6- 
16%) under reducing conditions. 
knowledge and of the available data. A posttranslational mod- 
ification, the synthesis of a regulatory subunit and oligomer- 
ization of receptor, is a mechanism capable of modifying the 
affinity of receptors for their ligands. 
(d)  PMA causes an increase in the  heterogeneity of the 
uPAR leading  to a  decrease in electrophoretic mobility of 
uPAR and increase of the acid charges (Fig. 7). Whether this 
is due to synthesis of regulatory subunits or to posttransla- 
tional modification remains to be seen. 
uPAR and Differentiation 
PMA induces the differentiation of monocyte-like U937 cells 
into macrophage-like cells. This entails a block of cell divi- 
sion, a major phenotypic change with expression of specific 
macrophage functions,  like phagocytosis,  and synthesis of 
surface markers (42,  49).  The observed increase of uPAR 
synthesis and decrease in affinity may be part of this differen- 
tiation  program.  In  fact,  we  have  previously  shown  that 
nonadherent  and  adherent  PMA-treated  U937  cells  show 
different levels of induction of uPAR even though they have 
been exposed to the same dose of PMA (57). 
Two Populations of uPARs 
Induction in U937 cells of uPAR synthesis and decrease of 
affinity, two effects that should have opposite regulatory con- 
sequences,  arouse  further  interest.  The PMA-induced  de- 
crease in affinity is a novel regulatory mechanism capable of 
modifying the ratio between soluble and surface-bound uPA; 
i.e., regulating the location of uPA.  This effect might cause 
Picone et al. Regulation of Urokinase Receptors  699 either in different cells or in the same cells, but in response 
to different stimuli. 
Although nothing is yet known of the physiological signal 
for the affinity-regulating mechanism,  it seems to us that it 
may be connected with the level and the localization of the 
uPA activity on the cell  surface.  On the other hand, PMA 
is a fast regulator of the activity of several types of receptors. 
Binding of epidermal growth factor (36, 55), insulin (61), and 
somatomedin (44) is affected by PMA treatment. Down-reg- 
ulation and increased internalization (6, 16, 22, 34, 55) have 
been reported.  PMA activates protein kinase C (15), which 
in turn phosphorylates the epidermal growth factor receptor 
at  a  specific  threonine residue,  causing  a  decrease  of the 
affinity for epidermal growth factor (18, 23, 25, 33, 34). The 
effect of PMA on uPAR affinity suggests that the uPAR also 
is directly or indirectly affected by protein kinase C. 
The presence of two populations of receptor molecules ap- 
pears to be rather common in mammalian cells (9, 52-54). 
The modulation of the uPAR molecules may represent an im- 
portant feature in the regulation of extracellular proteolysis 
and thus of the degradation of extracellular matrix and base- 
ment membrane components, processes that are at the core 
of cell migration and invasiveness.  Since uPARs are present 
in several blood and endothelial cells, their regulation might 
also significantly affect  intravascular  fibrinolytic activity in 
physiological, pathological, and pharmacological conditions 
(10). 
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Figure 7.  Bidimensional  gel electrophoresis  of t25I-ATF cross-linked 
control  (A)  and PMA-treated  (100  nM,  72 h) (B) U937 cells.  The 
internal  markers  are  indicated.  The arrow  represents  an unidenti- 
fied marker protein.  C  shows a  reconstructed  composite  picture of 
A  and B. 
an inversion of the medium/cell ratio of uPA activity as ob- 
served  in PMA-treated  transformed  mouse  fibroblasts  (7). 
No information is available at this time on the physiological 
significance of the apparently contradictory combination of 
the above effects of PMA on uPARs.  It is possible that the 
effects on synthesis and affinity of uPARs normally take place 
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